Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenylephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.96 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.96 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.96 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.96 |
| ▸ | HTR1A | P08908 | 2/20 | 0.96 |
| ▸ | TSHR | P16473 | 2/20 | 0.96 |
| ▸ | DRD1 | P21728 | 2/20 | 0.96 |
| ▸ | DRD3 | P35462 | 2/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
| ▸ | HTR7 | P34969 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylephrine SCHEMBL30800718 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL21829033 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL412215 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL5053821 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL30104947 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL3643743 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL24655 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL24654 | 1.00 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL5958774 | 0.98 | HIF1A (0.97) | HIF1AKDM4ELMNABLMGAA | |
| Phenylephrine SCHEMBL4711 | 0.98 | HIF1A (1.00) | HIF1AKDM4ELMNABLMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295740-A1 | Neurotoxin Compositions with Increased Efficacy and Effect Duration | BIOPHARMA CREDIT PLC [AS COLLATERAL AGENT] (GB) | 2025-09-25 | — | — | US | disclosed |
| US-20250275983-A1 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | Sydnexis, Inc. | 2025-09-04 | — | — | US | disclosed |
| EP-3901283-B1 | THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS | INBIOMOTION SL (ES) | 2025-08-06 | — | — | EP | disclosed |
| EP-4580666-A2 | NEUROTOXIN COMPOSITIONS WITH INCREASED EFFICACY AND EFFECT DURATION | Evolus, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250186251-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | Sydnexis, Inc. | 2025-06-12 | — | — | US | disclosed |
| CN-119790137-A | Human nasal organoids and methods of making and using the same | 港大科桥有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12196758-B2 | Method for the prognosis and treatment of cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) and INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2025-01-14 | — | — | US | disclosed |
| US-12168017-B2 | D2O stabilized pharmaceutical formulations | Sydnexis, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240390668-A1 | CURED RING SEAL | COCHLEAR LIMITED (AU) | 2024-11-28 | — | — | US | disclosed |
| EP-4456886-A1 | PHENYLEPHRINE PREMIX FORMULATIONS AND USES THEREOF | BAXTER INTERNATIONAL INC. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20230381209-A1 | THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS | INBIOMOTION S.L. (ES) | 2023-11-30 | — | — | US | disclosed |
| US-20230381016-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | Sydnexis, Inc. | 2023-11-30 | — | — | US | disclosed |
| CN-109790582-B | C-MAF state based therapeutic treatment of breast cancer | 生物运动有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023129926-A1 | PHENYLEPHRINE PREMIX FORMULATIONS AND USES THEREOF | BAXTER INTERNATIONAL INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023031711-A1 | CURED RING SEAL | COCHLEAR LIMITED (AU) | 2023-03-09 | — | — | WO | disclosed |
| US-11596642-B2 | Therapeutic treatment of breast cancer based on c-MAF status | INBIOMOTION S.L. (ES) | 2023-03-07 | — | — | US | disclosed |
| WO-2023002270-A1 | SELF-PROPELLED PHARMACEUTICAL DELIVERY CAPSULES | COCHLEAR LIMITED (AU) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022269540-A1 | METHODS AND PHARMACEUTICAL FORMULATIONS FOR MODULATING THE PROPERTIES OF THE BLOOD LABYRINTH BARRIER | COCHLEAR LIMITED (AU) | 2022-12-29 | — | — | WO | disclosed |
| US-11352673-B2 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) | 2022-06-07 | — | — | US | disclosed |
| US-20220042997-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | INBIOMOTION S.L. (ES) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186251-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | CHRM3, CHRM2, CHRM4 | ADRA1A 17/4885ADRA1B 18/4885ADRA1D 7/4885 |
| US-20220042997-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | MAFG, MAFK, ACP3 | ADRA1A 1553/4885ADRA1B 1146/4885ADRA1D 2084/4885 |
| US-12196758-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | ADRA1A 872/4885ADRA1B 487/4885ADRA1D 2060/4885 |
| US-12168017-B2 | D2O stabilized pharmaceutical formulations | AQP1, AQP3, CRYZ | ADRA1A 649/4885ADRA1B 999/4885ADRA1D 318/4885 |
| US-20250275983-A1 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | AQP1, AQP3, CRYZ | ADRA1A 649/4885ADRA1B 999/4885ADRA1D 318/4885 |
| US-11352673-B2 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | MAFG, MAFK, MYCBP | ADRA1A 1982/4885ADRA1B 1746/4885ADRA1D 2641/4885 |
| US-20230381016-A1 | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF | CHRM3, CHRM2, CHRM4 | ADRA1A 17/4885ADRA1B 18/4885ADRA1D 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.